TTFields (Optune Lua) for Mesothelioma: 18.2-Month STELLAR Survival

Tumor Treating Fields (TTFields), delivered by the wearable Optune Lua device, are an FDA-authorized treatment for unresectable pleural mesothelioma that work through electric fields rather than drugs. In the STELLAR trial, patients who added TTFields to chemotherapy had a median overall survival of 18.2 months — compared with about 12.1 months from the historical chemotherapy benchmark — though the trial had no randomized control arm [1].

For patients and families weighing where this device fits among newer options, the Mesothelioma Treatment Options reference at WikiMesothelioma [9] and the firm's overview of how the NCCN guidelines rank mesothelioma treatments provide companion context to the evidence reviewed below.

What Are the Key Facts About TTFields for Mesothelioma?

• Optune Lua delivers Tumor Treating Fields — alternating electric fields tuned to about 150 kHz — through four arrays worn on the chest [1][2]
• The device is FDA-authorized for unresectable pleural mesothelioma in combination with pemetrexed and platinum chemotherapy [5]
• The pivotal STELLAR trial reported a median overall survival of 18.2 months, versus roughly 12.1 months for the historical chemotherapy benchmark [1][4]
• STELLAR was a single-arm phase 2 trial of 80 patients with no randomized control group — its central limitation [1]
• One-year overall survival in STELLAR was 62% [1]
• The FDA cleared the device in May 2019 through the Humanitarian Device Exemption pathway (H180002) [5]
• Recommended wear time is at least 18 hours per day, and compliance correlates with outcomes [1]
• The most common side effect is skin irritation under the arrays (about 30–40% of users); the device causes no systemic drug toxicity [1][2]
• As of 2026, no randomized phase 3 trial of TTFields in mesothelioma has been completed or registered [1][2]
• Since 2020, nivolumab plus ipilimumab has become the preferred first-line option for many patients, so TTFields is most often used in chemotherapy-based first-line care [3]

What Are Tumor Treating Fields, and How Does Optune Lua Work?

• TTFields are low-intensity (1–2 V/cm), intermediate-frequency (100–500 kHz) alternating electric fields applied non-invasively through skin-surface transducer arrays [2]
• For pleural mesothelioma, the fields are tuned to approximately 150 kHz, the frequency that most effectively disrupts this cancer's dividing cells [1]
• The fields interfere with the mitotic spindle during cell division, preventing chromosomes from separating normally [2]
• They also concentrate at the cleavage furrow during cytokinesis, disrupting the final physical separation into two daughter cells [2]
• Rapidly dividing cancer cells are selectively affected; slow-dividing normal adult tissue is largely spared [2]
• Optune Lua is worn through four transducer arrays placed on the chest wall and back, powered by a rechargeable portable generator [5]
• The device is approved for use in combination with pemetrexed and platinum chemotherapy — not as a standalone therapy [5]
• Because it acts locally through electric fields, the main side effect is skin irritation rather than systemic drug toxicity [1]

This mechanism, and where the therapy now stands in mesothelioma care, is summarized in a 2025 review of TTFields in unresectable pleural mesothelioma led by the STELLAR investigators, which describes how the alternating fields disrupt dividing tumor cells alongside the device's efficacy and safety profile [2]. The key insight is selectivity: dividing cells are vulnerable to the fields, while the post-mitotic cells that make up most healthy adult tissue are not.

What Did the STELLAR Trial Show for Mesothelioma?

The evidence supporting Optune Lua in mesothelioma comes primarily from STELLAR, a phase 2, single-arm trial of 80 patients with previously untreated, unresectable malignant pleural mesothelioma, published in The Lancet Oncology [1]. Every patient received TTFields at 150 kHz combined with pemetrexed plus cisplatin or carboplatin; there was no separate chemotherapy-only comparison group.

Outcome	STELLAR (TTFields + chemotherapy)	Historical chemotherapy benchmark
Median overall survival	18.2 months	≈ 12.1 months
1-year overall survival	62%	≈ 50%
Median progression-free survival	7.6 months	≈ 5.7 months

The 18.2-month median survival is one of the higher figures reported in a frontline mesothelioma study, and it compares favorably with the roughly 12.1-month benchmark established by pemetrexed-plus-cisplatin chemotherapy in the earlier EMPHACIS trial [1][4]. In a disease where advances have historically been measured in weeks, a difference of this size drew significant attention.

"Eighteen months is a genuinely encouraging number in mesothelioma, and families deserve to know it exists. But I always explain the same caveat the researchers did: STELLAR compared its patients to a historical benchmark, not to a control group enrolled at the same time. That design means the device looks promising — it does not prove the fields alone produced the gain. Honesty about that distinction is what lets a family make a real decision rather than a hopeful guess."

— David Foster, Executive Director of Client Services, Danziger & De Llano

That single-arm design is the central scientific limitation. Without patients randomly assigned to chemotherapy with or without TTFields, the comparison to historical outcomes cannot rule out that differences in patient selection, supportive care, or the era of treatment contributed to the result. As of 2026, no randomized phase 3 trial of TTFields in mesothelioma has been completed or registered, so this limitation has not yet been resolved by stronger evidence.

Is Optune Lua FDA-Approved for Mesothelioma?

Yes — with an important nuance about the pathway. The FDA authorized the device, originally cleared as the NovoTTF-100L System and now marketed as Optune Lua, in May 2019 through the Humanitarian Device Exemption (HDE) pathway [5]. The authorization covers use with pemetrexed and platinum-based chemotherapy in adults with unresectable, locally advanced or metastatic malignant pleural mesothelioma.

The HDE pathway matters because it is not the same as standard premarket approval. It is reserved for devices that treat or diagnose conditions affecting small patient populations, and it requires a demonstration of probable benefit rather than the large randomized evidence the FDA usually requires. Mesothelioma — with roughly 3,000 U.S. cases a year — qualifies as exactly the kind of rare condition the pathway was designed for. The practical result is that Optune Lua is a legitimately FDA-authorized mesothelioma treatment, covered by Medicare and most commercial insurers for its approved indication, while still resting on single-arm rather than randomized evidence.

Where Does TTFields Fit in the 2026 Mesothelioma Treatment Algorithm?

The treatment landscape shifted substantially after STELLAR was published. In 2020, the CheckMate 743 trial established that dual immunotherapy with nivolumab plus ipilimumab improved survival over chemotherapy, and it has since become the preferred first-line systemic therapy for many patients with unresectable disease, carrying the strongest evidence rating in U.S. guidelines [3]. That changed where TTFields sits.

Patient situation	How TTFields typically fits
Choosing a chemotherapy-based first line	TTFields plus pemetrexed and platinum is a reasonable option to intensify chemotherapy without adding systemic drug toxicity
Cannot receive immunotherapy (autoimmune disease, steroid use, organ transplant)	One of the more attractive alternatives, since it adds no immune-related risk
Eligible for and choosing immunotherapy	Nivolumab plus ipilimumab is generally preferred first; combining it with TTFields is investigational

An open research question is whether TTFields could be combined with immunotherapy rather than chemotherapy. Laboratory data suggest the fields may make tumors more visible to the immune system by releasing tumor antigens from dying cells, a potential synergy with checkpoint inhibitors. A phase 2 trial is studying TTFields combined with pembrolizumab in pleural mesothelioma, but no randomized results are available as of 2026 [7]. Patients interested in that combination would generally need to enroll in a study; the Clinical Trials for Mesothelioma reference at WikiMesothelioma [11] outlines how trial participation works.

What Are the Side Effects and Daily Demands of Wearing Optune Lua?

The side-effect profile is one of the device's clearest advantages and is fundamentally different from systemic therapy. Because TTFields acts locally, it does not cause the bone-marrow suppression, nausea, or immune-related toxicity associated with chemotherapy and immunotherapy [1].

Effect or demand	What to expect
Skin irritation / contact dermatitis under arrays	Most common effect (≈30–40% of users); managed with topical steroids, skin care, and rotating array placement
Systemic toxicity	None attributable to the device itself — a key contrast with drug therapy
Daily wear time	Target of at least 18 hours per day; higher compliance is associated with better outcomes
Array changes	Replaced every 2–3 days by the patient or a caregiver at home
Device weight	Portable rechargeable generator of roughly 1 kg, worn during normal daily activity

The trade-off is commitment rather than toxicity. Wearing a device at least 18 hours a day, every day, and maintaining the skin under the arrays is a real lifestyle adjustment — and because compliance is tied to results, the therapy rewards patients who can keep to the wear-time target. Novocure provides technical support and device-replacement services to help patients sustain that routine.

Who Is the Best Candidate for Optune Lua?

The device suits a specific profile. The strongest candidates are adults with unresectable pleural mesothelioma who are pursuing a chemotherapy-based first-line approach and can commit to the daily wear time — and especially patients who cannot receive immunotherapy because of an autoimmune condition, chronic steroid use, or a prior organ transplant.

• Well suited: Unresectable disease, good performance status, choosing chemotherapy first line, able to maintain 18+ hours of daily use
• Particularly useful: Patients for whom immunotherapy is contraindicated, since TTFields adds no immune-related risk
• Less suitable: Patients with implanted electrical devices such as pacemakers, significant chest-wall skin conditions, or circumstances that make consistent daily use difficult

"The families I talk to who do best with this device are the ones who go in clear-eyed about what it asks. It is eighteen hours a day, every day, and someone at home usually has to help with the arrays. When a patient and a caregiver understand that up front and decide together that they can do it, the device fits their life. When they are told it is effortless, it doesn't. My job is to make sure families hear the honest version before they choose."

— David Foster, Executive Director of Client Services, Danziger & De Llano

As with every mesothelioma treatment decision, the choice is best made with a specialist who can compare the device against immunotherapy and chemotherapy for the individual patient. The Pleural Mesothelioma overview at WikiMesothelioma [10] and the National Cancer Institute's Mesothelioma Treatment (PDQ) summary [8] are useful companions when discussing options, and families researching where to receive care can review the mesothelioma treatment centers reference at Mesothelioma.net [13].

References

1. [1] Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. The Lancet Oncology. 2019;20(12):1702–1709. PMID: 31628016.
2. [2] Ceresoli GL, Gianoncelli L. Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook. Current Treatment Options in Oncology. 2025. PMID: 40266436.
3. [3] Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375–386. PMID: 33485464.
4. [4] Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 2003;21(14):2636–2644. PMID: 12860938.
5. [5] U.S. Food and Drug Administration. Humanitarian Device Exemption — NovoTTF-100L System (Optune Lua), H180002. accessdata.fda.gov. May 23, 2019.
6. [6] ClinicalTrials.gov. Pivotal Effect of TTFields With Chemotherapy in Mesothelioma (STELLAR), NCT02397928. clinicaltrials.gov.
7. [7] ClinicalTrials.gov. Tumor Treating Fields With Pembrolizumab in Pleural Mesothelioma, NCT04885998. clinicaltrials.gov.
8. [8] National Cancer Institute. Mesothelioma Treatment (PDQ) – Health Professional Version. Cancer.gov. Accessed June 2026.
9. [9] WikiMesothelioma. Mesothelioma Treatment Options. wikimesothelioma.com/Treatment_Options.
10. [10] WikiMesothelioma. Pleural Mesothelioma. wikimesothelioma.com/Pleural_Mesothelioma.
11. [11] WikiMesothelioma. Clinical Trials for Mesothelioma. wikimesothelioma.com/Clinical_Trials_Mesothelioma.
12. [12] Danziger & De Llano. Mesothelioma Lawyers. dandell.com.
13. [13] Mesothelioma.net. Mesothelioma Treatment Centers. mesothelioma.net/mesothelioma-treatment-centers.